| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
BIBR 1087 SE (BIBR-1087SE; Desethyl Dabigatran Etexilate) is a metabolite of dabigatran etexilate (BIBR-1048), which is the prodrug of dabigatran (an anticoagulant drug and blood thinner).
| Targets |
Dabigatran etexilate metabolite/intermediate
|
|---|---|
| Additional Infomation |
This open-label, parallel-group study evaluated the effects of moderate hepatic impairment on the pharmacokinetics (PK) and pharmacodynamics (PD) of dabigatran etexilate. Healthy volunteers (n = 12) and patients with hepatic impairment (Child-Pugh B; n = 12) received a single oral dose of 150 mg dabigatran etexilate. The mean area under the concentration-time curve, terminal half-life, and renal clearance of dabigatran were comparable between the hepatic-impaired and healthy volunteers. The conversion of the dabigatran intermediate BIBR1087 to active dabigatran was slower in patients with hepatic impairment, indicating partial hepatic involvement in the biotransformation of dabigatran etexilate. However, the total drug exposure was comparable between the two groups; therefore, this observation had no clinical significance for the anticoagulant activity of dabigatran. Hepatic disease did not alter the glucuronidation of dabigatran; glucuronidation capacity was maintained in patients with moderate hepatic impairment. Activated partial thromboplastin time, eccarin clotting time, and thrombin time were substantially similar between the two groups. This study indicates that moderate hepatic impairment does not affect the pharmacokinetics/pharmacodynamics or safety of dabigatran. Therefore, patients with moderate hepatic impairment can take dabigatran etexilate without dose adjustment. [1]
|
| Molecular Formula |
C₃₂H₃₇N₇O₅
|
|---|---|
| Molecular Weight |
599.68
|
| Exact Mass |
599.285
|
| CAS # |
212321-78-3
|
| Related CAS # |
Dabigatran etexilate;211915-06-9
|
| PubChem CID |
135565549
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
853.4±75.0 °C at 760 mmHg
|
| Flash Point |
469.9±37.1 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.636
|
| LogP |
4.14
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
44
|
| Complexity |
959
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCOC(=O)NC(=N)c1ccc(NCc2nc3cc(ccc3n2C)C(=O)N(CCC(O)=O)c2ccccn2)cc1
|
| InChi Key |
UGEWTLXHMYKLCO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C32H37N7O5/c1-3-4-5-8-19-44-32(43)37-30(33)22-10-13-24(14-11-22)35-21-28-36-25-20-23(12-15-26(25)38(28)2)31(42)39(18-16-29(40)41)27-9-6-7-17-34-27/h6-7,9-15,17,20,35H,3-5,8,16,18-19,21H2,1-2H3,(H,40,41)(H2,33,37,43)
|
| Chemical Name |
3-[[2-[[4-(N-hexoxycarbonylcarbamimidoyl)anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoic acid
|
| Synonyms |
Desethyl Dabigatran Etexilate; BIBR 1087 SE; 212321-78-3; Desethyl Dabigatran Etexilate; BIBR-1087SE; Desethyldabigatran Etexilate; BIBR 1087; BIBR-1087; 441X78E2Z0; (E)-3-(2-(((4-(N'-((Hexyloxy)carbonyl)carbamimidoyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoic acid; BIBR-1087 SE
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~416.89 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.47 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.47 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.47 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6676 mL | 8.3378 mL | 16.6756 mL | |
| 5 mM | 0.3335 mL | 1.6676 mL | 3.3351 mL | |
| 10 mM | 0.1668 mL | 0.8338 mL | 1.6676 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
